N-(2-氨基甲基)环丙胺 | 62491-85-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-(2-氨基甲基)环丙胺
• 英文名称: N'-cyclopropylethane-1,2-diamine
• 英文别名: cyclopropylethylenediamine；N-Cyclopropyl-aethylendiamin；N-(2-aminoethyl)cyclopropanamine
• CAS: 62491-85-4
• 化学式: C₅H₁₂N₂
• mdl: MFCD11593966
• 分子量: 100.164
• InChiKey: BUMRERJTUCBSQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  7
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2921300090

反应信息

• 作为反应物：
  描述：

  N-(2-氨基甲基)环丙胺 、 磺酰胺 以 吡啶 为溶剂， 生成 2-cyclopropyl-1,2,5-thiadiazolidine 1,1-dioxide
  参考文献：
  名称：

  [EN] ASPARTYL PROTEASE INHIBITORS
  [FR] INHIBITEURS DE L'ASPARTYL-PROTEASE

  摘要：

  本发明提供具有以下结构的化合物（I）：其中R'、R0、R1、X1、R2、R3、R3'、X2、X3和R4如本文所定义，并且其药物组合物。本发明还提供抑制蛋白酶的方法，更具体地是天冬氨酸蛋白酶。在某些实施例中，这些化合物抑制BACE（β-APP裂解酶），因此可用于治疗或预防大脑中存在β-淀粉样沉积的疾病（包括但不限于阿尔茨海默病）。本发明还提供了制备本发明化合物的方法。

  公开号：

  WO2003106405A1
• 作为产物：
  描述：

  N-acetyl-N'-cyclopropylethylenediamine 在 盐酸 作用下， 反应 2.0h， 生成 N-(2-氨基甲基)环丙胺
  参考文献：
  名称：

  Synthesis and preliminary data on new selective and potent gastric prokinetic substituted benzamides

  摘要：

  A series of amino-halogen-N-[2-aminoethyl] benzamides was synthesized and evaluated for enhancing gastric emptying. Compared to metoclopramide, domperidone and bromopride, a number of compounds were shown to be more active in enhancing gastric motility (rat stomach emptying), devoid of dopaminergic D2-receptor antagonism (rat apomorphine test) and to be less toxic.

  DOI：

  10.1016/0223-5234(93)90129-3

文献信息

• Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy
  作者：Beatriz Baragaña、Neil R. Norcross、Caroline Wilson、Achim Porzelle、Irene Hallyburton、Raffaella Grimaldi、Maria Osuna-Cabello、Suzanne Norval、Jennifer Riley、Laste Stojanovski、Frederick R. C. Simeons、Paul G. Wyatt、Michael J. Delves、Stephan Meister、Sandra Duffy、Vicky M. Avery、Elizabeth A. Winzeler、Robert E. Sinden、Sergio Wittlin、Julie A. Frearson、David W. Gray、Alan H. Fairlamb、David Waterson、Simon F. Campbell、Paul Willis、Kevin D. Read、Ian H. Gilbert

  DOI：10.1021/acs.jmedchem.6b00723

  日期：2016.11.10

  The antiplasmodial activity, DMPK properties, and efficacy of a series of quinoline-4-carboxamides are described. This series was identified from a phenotypic screen against the blood stage of Plasmodium falciparum (3D7) and displayed moderate potency but with suboptimal physicochemical properties and poor microsomal stability. The screening hit (1, EC50 = 120 nM) was optimized to lead molecules with

  描述了一系列 quinoline-4-carboxamides 的抗疟原虫活性、DMPK 特性和功效。该系列是从针对恶性疟原虫 (3D7) 血液阶段的表型筛选中确定的，显示出中等效力，但物理化学性质不理想，微粒体稳定性较差。筛选命中 (1, EC50 = 120 nM) 被优化为具有低纳摩尔体外效力的先导分子。药代动力学特征的改进导致几种化合物在伯氏疟原虫疟疾小鼠模型中显示出优异的口服功效，当口服给药 4 天时，ED90 值低于 1 mg/kg。有利的效力、选择性、DMPK 特性和功效，加上新的作用机制，抑制翻译延伸因子 2 (PfEF2)，
• N-cycloalkylaminoethylbenzamide derivatives, their synthesis and
  申请人：Poli Industria Chimica S.p.A.

  公开号：US05010108A1

  公开（公告）日：1991-04-23

  New N-(2-cycloalkylamino)ethyl-substituted benzamides having a powerful stimulating activity on gastric motility and with a low central anti-dopaminergic activity are described. The synthesis and the pharmaceutical preparation for therapeutical use are also described.

  本文介绍了一种具有强烈胃动力刺激活性且中枢抗多巴胺活性较低的新型N-(2-环烷基氨基)乙基取代苯甲酰胺。同时还介绍了其合成方法和制备方法，用于治疗。
• Structure–Activity Relationships of 4-Position Diamine Quinoline Methanols as Intermittent Preventative Treatment (IPT) against <i>Plasmodium falciparum</i>
  作者：Erin Milner、Sean Gardner、Jay Moon、Kristina Grauer、Jennifer Auschwitz、Ian Bathurst、Diana Caridha、Lucia Gerena、Montip Gettayacamin、Jacob Johnson、Michael Kozar、Patricia Lee、Susan Leed、Qigui Li、William McCalmont、Victor Melendez、Norma Roncal、Richard Sciotti、Bryan Smith、Jason Sousa、Anchalee Tungtaeng、Peter Wipf、Geoffrey Dow

  DOI：10.1021/jm200647u

  日期：2011.9.22

  A library of diamine quinoline methanols were designed based on the mefloquine scaffold. The systematic variation of the 4-position amino alcohol side chain led to analogues that maintained potency while reducing accumulation in the central nervous system (CNS). Although the mechanism of action remains elusive, these data indicate that the 4-position side chain is critical for activity and that potency (as measured by IC(90)) does not correlate with accumulation in the CNS. A new lead compound, (S)-1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-(2-(cyclopropylamino)ethylamino)ethanol (WR621308), was identified with single dose efficacy and substantially lower permeability across MDCK cell monolayers than mefloquine. This compound could be appropriate for intermittent preventative treatment (IPTx) indications or other malaria treatments currently approved for mefloquine.